Han Kun advises Sinovac LS on its US$500 million financing for COVID-19 vaccine project
2020-12-07
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, recently announced that Sinovac Life Sciences Co., Ltd. ("Sinovac LS"), a subsidiary of Sinovac Biotech Ltd., has secured approximately US$500 million in funding for further development, capacity expansion and manufacturing of CoronaVac, its COVID-19 vaccine candidate, as well as to conduct other development and operational activities.
Han Kun, acting as PRC legal counsel to Sinovac LS, provided legal services throughout the transaction, including providing legal advice on the transaction structure, drafting and negotiating transaction documents, and assisting Sinovac LS in closing the transaction.